Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

410 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD).
Nadarajah VD, van Putten M, Chaouch A, Garrood P, Straub V, Lochmüller H, Ginjaar HB, Aartsma-Rus AM, van Ommen GJ, den Dunnen JT, 't Hoen PA. Nadarajah VD, et al. Among authors: van ommen gj, van putten m. Neuromuscul Disord. 2011 Aug;21(8):569-78. doi: 10.1016/j.nmd.2011.05.011. Epub 2011 Jul 2. Neuromuscul Disord. 2011. PMID: 21724396 Free article.
Common pathological mechanisms in mouse models for muscular dystrophies.
Turk R, Sterrenburg E, van der Wees CG, de Meijer EJ, de Menezes RX, Groh S, Campbell KP, Noguchi S, van Ommen GJ, den Dunnen JT, 't Hoen PA. Turk R, et al. Among authors: van der wees cg, van ommen gj. FASEB J. 2006 Jan;20(1):127-9. doi: 10.1096/fj.05-4678fje. Epub 2005 Nov 23. FASEB J. 2006. PMID: 16306063
Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor.
Kemaladewi DU, Pasteuning S, van der Meulen JW, van Heiningen SH, van Ommen GJ, Ten Dijke P, Aartsma-Rus A, 't Hoen PA, Hoogaars WM. Kemaladewi DU, et al. Among authors: van der meulen jw, van ommen gj, van heiningen sh. Mol Ther Nucleic Acids. 2014 Apr 1;3(4):e156. doi: 10.1038/mtna.2014.7. Mol Ther Nucleic Acids. 2014. PMID: 24691207 Free PMC article.
Innovating therapies for muscle diseases.
Aartsma-Rus A, Van Ommen GJ, Kaplan JC. Aartsma-Rus A, et al. Among authors: van ommen gj. Handb Clin Neurol. 2013;113:1497-501. doi: 10.1016/B978-0-444-59565-2.00020-4. Handb Clin Neurol. 2013. PMID: 23622373 Review.
Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP).
Yılmaz-Eliş AS, Aartsma-Rus A, 't Hoen PA, Safdar H, Breukel C, van Vlijmen BJ, van Deutekom J, de Kimpe S, van Ommen GJ, Verbeek JS. Yılmaz-Eliş AS, et al. Among authors: van vlijmen bj, van deutekom j, van ommen gj. Mol Ther Nucleic Acids. 2013 Jan 22;2(1):e66. doi: 10.1038/mtna.2012.58. Mol Ther Nucleic Acids. 2013. PMID: 23340324 Free PMC article.
Antisense oligonucleotide mediated exon skipping as a potential strategy for the treatment of a variety of inflammatory diseases such as rheumatoid arthritis.
Yilmaz-Elis S, Aartsma-Rus A, Vroon A, van Deutekom J, de Kimpe S, 't Hoen PA, van Ommen GJ, Verbeek JS. Yilmaz-Elis S, et al. Among authors: van deutekom j, van ommen gj. Ann Rheum Dis. 2012 Apr;71 Suppl 2:i75-7. doi: 10.1136/annrheumdis-2011-200971. Ann Rheum Dis. 2012. PMID: 22460143 No abstract available.
Therapeutic exon skipping for dysferlinopathies?
Aartsma-Rus A, Singh KH, Fokkema IF, Ginjaar IB, van Ommen GJ, den Dunnen JT, van der Maarel SM. Aartsma-Rus A, et al. Among authors: van der maarel sm, van ommen gj. Eur J Hum Genet. 2010 Aug;18(8):889-94. doi: 10.1038/ejhg.2010.4. Epub 2010 Feb 10. Eur J Hum Genet. 2010. PMID: 20145676 Free PMC article.
410 results